Pharmacogenetic considerations when prescribing cholinesterase inhibitors for the treatment of Alzheimer’s disease

References

• Cacabelos R, Fernández-Novoa L, Lombardi V, et al. Molecular genetics of Alzheimer’s disease and aging. Meth. Find. Exp. Clin. Pharmacol.. 2005;27:1–573.
   Google Scholar
• Cacabelos R. Pharmacogenomics in Alzheimer’s disease. Methods Mol Biol. 2008;448:213–357.
   Google Scholar
• Cacabelos R, Cacabelos P, Torrellas C, et al. Pharmacogenomics of Alzheimer’s disease: novel therapeutic strategies for drug development. Methods Mol Biol. 2014;1175:323–556.
   Google Scholar
• Cacabelos R, Carril JC, Cacabelos P, et al. Pharmacogenomics of Alzheimer’s Disease: genetic determinants of phenotypic variation and therapeutic outcome. J. Genomic Med. Pharmacogenomics.. 2016;1:151–209.
   Google Scholar
• Cacabelos R, Carril JC, Cacabelos N, et al. Sirtuins in Alzheimer’s disease: SIRT2-related genophenotypes and implications for pharmacoepigenetics. Int J Mol Sci. 2019;20(5):E1249.
   Google Scholar
• Arvanitakis Z, Shah RC, Bennett DA. Diagnosis and management of dementia: review. JAMA. 2019;322(16):1589–1599.
   Google Scholar
• Davies P, Maloney AJF. Selective loss of central cholinergic neurons in Alzheimer’s disease. Lancet. 1976;2(8000):1403.
   Google Scholar
• Bowen DM, Smith CB, White P, et al. Neurotransmitter-related enzymes and indices of hypoxia in senile dementia and other abiotrophies. Brain. 1976;99(3):459–496.
   Google Scholar
• Whitehouse PJ, Price DL, Struble RG, et al. Alzheimer’s disease and senile dementia: loss of neurons in the basal forebrain. Science. 1982;215:1237–1239.
   Google Scholar
• Summers WK, Kaufman KA, Altman F. THA-a review of the literature and its use in treatment of five overdose patients. Clin Toxicol. 1980;16(3):269–281.
   Google Scholar
• Summers WK, Majovski LV, Marsh GM, et al. Oral tetrahydroaminoacridine in long-term treatment of senile dementia, Alzheimer type. N Engl J Med. 1986;315(20):1241–1245. 13.
   Google Scholar
• Summers WK, Koehler AL, Marsh GM, et al. Long-term hepatotoxicity of tacrine. Lancet. 1989;1(8640):729.
   Google Scholar
• Alzheimer Disease Agents. LiverTox: clinical and research information on drug-induced liver injury [internet]. Bethesda (MD): National Institute of Diabetes and Digestive and Kidney Diseases. 2012-. 2020. p. Jan. 15.
   Google Scholar
• Cacabelos R. Have there been improvement in Alzheimer’s disease drug discovery over the past 5 years? Expert Opin Drug Discov. 2018;13(6):523–538.
   Google Scholar
• Moraes FS, Souza MLC, Lucchetti G, et al. Trends and disparities in the use of cholinesterase inhibitors to treat Alzheimer’s disease dispensed by the Brazilian public health system - 2008 to 2014: a nation-wide analysis. Arq Neuropsiquiatr. 2018;76(7):444–451.
   Google Scholar
• Thorpe CT, Fowler NR, Harrigan K, et al. Racial and ethnic differences in initiation and discontinuation of antidementia drugs by medicare beneficiaries. J Am Geriatr Soc. 2016;64(9):1806–1814.
   Google Scholar
• Petit AE, Mangeard H, Chazard E, et al. Changes in drug management of Alzheimer’s disease in nursing homes: impact of the media campaign against specific drugs for Alzheimer’s disease. Encephale. 2017;43(1):21–26.
   Google Scholar
• Wang JH, Wu YJ, Tee BL, et al. Medical comorbidity in Alzheimer’s disease: a nested case-control study. J Alzheimers Dis. 2018;63(2):773–781.
   Google Scholar
• Cacabelos R, Cacabelos N, Carril JC. The role of pharmacogenomics in adverse drug reactions. Expert Rev Clin Pharmacol. 2019;12(5):407–442.
   Google Scholar
• Cacabelos R. Pharmacogenomics of drugs used to treat brain disorders. Expert Rev Precis Med Drug Dev. 2020;5(3):181–234.
   Google Scholar
• Valladales-Restrepo LF, Duran-Lengua M, Machado-Alba JE. Potentially inappropriate prescriptions of anticholinergics drugs in Alzheimer’s disease patients. Geriatr Gerontol Int. 2019;19(9):913–917.
   Google Scholar
• Schultz BR, Takeshita J, Goebert D, et al. Simultaneous usage of dementia medications and anticholinergics among Asians and Pacific Islanders. Psychogeriatrics. 2017;17(6):423–429.
   Google Scholar
• Hernández-Arroyo MJ, Díaz-Madero A. Risk/benefit assessment in the treatment of Alzheimer’s disease. drug interactions]. Rev Esp Geriatr Gerontol. 2016;51(4):191–195.
   Google Scholar
• Pirker-Kees A, Dal-Bianco P, Schmidt R. Effects of psychotropic medication on cognition, caregiver burden, and neuropsychiatric symptoms in alzheimer’s disease over 12 months: results from a prospective registry of dementia in Austria (prodem). J Alzheimers Dis. 2019;71(2):623–630.
   Google Scholar
• Bravo-José P, Sáez-Lleó CI, Peris-Martí JF. Deprescribing antipsychotics in long term care patients with dementia. Farm Hosp. 2019;43(4):140–145.
   Google Scholar
• Mantri S, Fullard M, Gray SL, et al. Patterns of dementia treatment and frank prescribing errors in older adults with Parkinson disease. JAMA Neurol. 2019;76(1):41–49.
   Google Scholar
• Zheng WY, Richardson LC, Li L, et al. Drug-drug interactions and their harmful effects in hospitalised patients: a systematic review and meta-analysis. Eur J Clin Pharmacol. 2018;74(1):15–27.
   Google Scholar
• Patel RI, Beckett RD. Evaluation of resources for analyzing drug interactions. J Med Libr Assoc. 2016;104(4):290–295.
   Google Scholar
• Shoshi A, Müller U, Shoshi A, et al. An ehealth system for biomedical risk analysis of drugs. Stud Health Technol Inform. 2017;236:128–135.
   Google Scholar
• Poirier J, Delisle MC, Quirion R, et al. Apolipoprotein E4 allele as a predictor of cholinergic deficits and treatment outcome in Alzheimer disease. Proc Natl Acad Sci U S A. 1995;92(26):12260–12264.
   Google Scholar
• Cacabelos R, Fernández-Novoa L, Pichel V, et al. Pharmacogenomic studies with a combination therapy in Alzheimer’s disease. In: Takeda M, Tanaka T, Cacabelos R, editors. Molecular neurobiology of Alzheimer’s disease and related disorders. Basel: Karger; 2004. p. 94–107.
   Google Scholar
• Cacabelos R. Pharmacogenomics of cognitive dysfunction and neuropsychiatric disorders in dementia. Int J Mol Sci. 2020;21(9):3059.
   Google Scholar
• Cacabelos R. World guide for drug use and pharmacogenomics. Corunna (SP): EuroEspes Publishing; 2012.
   Google Scholar
• Cacabelos R. Population-level pharmacogenomics for precision drug development in dementia. Expert Rev Precis Med Drug Dev. 2018;3(3):163–188.
   Google Scholar
• Cacabelos R. Epigenomic networking in drug development: from pathogenic mechanisms to pharmacogenomics. Drug Dev Res. 2014;75(6):348–365.
   Google Scholar
• Kozyra M, Ingelman-Sundberg M, Lauschke VM. Rare genetic variants in cellular transporters, metabolic enzymes, and nuclear receptors can be important determinants of interindividual differences in drug response. Genet Med. 2017;19(1):20–29.
   Google Scholar
• Zhou ZW, Chen XW, Sneed KB, et al. Clinical association between pharmacogenomics and adverse drug reactions. Drugs. 2015;75(6):589–631.
   Google Scholar
• Marcath LA, Pasternak AL, Hertz DL. Challenges to assess substrate-dependent allelic effects in CYP450 enzymes and the potential clinical implications. Pharmacogenomics J. 2019;19(6):501–515.
   Google Scholar
• Lesche D, Mostafa S, Everall I, et al. Impact of CYP1A2, CYP2C19, and CYP2D6 genotype- and phenoconversion-predicted enzyme activity on clozapine exposure and symptom severity. Pharmacogenomics J. 2020;20(2):192–201.
   Google Scholar
• Mesulam M. Cholinergic pathology of aging-mild cognitive impairment-Alzheimer’s disease continuum: functional and therapeutic implications. In: Giacobini E, Pepeu G, editors. The Brain Cholinergic System. Abindon (UK): Informa Healthcare; 2006. p. 47–58.
   Google Scholar
• Ferreira-Vieira TH, Guimaraes IM, Silva FR, et al. Alzheimer’s disease: targeting the Cholinergic System. Curr Neuropharmacol. 2016;14(1):101–115.
   Google Scholar
• Blusztajn JK, Berse B. The cholinergic neuronal phenotype in Alzheimer’s disease. Metab Brain Dis. 2000;15(1):45–64.
   Google Scholar
• Gau JT, Steinhilb ML, Kao TC, et al. Stable beta-secretase activity and presynaptic cholinergic markers during progressive central nervous system amyloidogenesis in Tg2576 mice. Am J Pathol. 2002;160(2):731–738.
   Google Scholar
• Erickson JD, Varoqui H, Schafer MKH, et al. Functional identification of a vesicular acetylcholine transporter and its expression from a ‘cholinergic’ gene locus. J Biol Chem. 1994;269(35):21929–21932.
   Google Scholar
• Oda Y. Choline acetyltransferase: the structure, distribution and pathologic changes in the central nervous system. Pathol Int. 1999;49(11):921–937.
   Google Scholar
• Ohno K, Tsujino A, Brengman JM, et al. Choline acetyltransferase mutations cause myasthenic syndrome associated with episodic apnea in humans. Proc Nat Acad Sci. 2001;98(4):2017–2022.
   Google Scholar
• Kraner S, Laufenberg I, Strassburg HM, et al. Congenital myasthenic syndrome with episodic apnea in patients homozygous for a CHAT missense mutation. Arch Neurol. 2003;60(5):761–763.
   Google Scholar
• Harold D, Peirce T, Moskvina V, et al. Sequence variation in the CHAT locus shows no association with late-onset Alzheimer’s disease. Hum Genet. 2003;113(3):258–267.
   Google Scholar
• Rigby MJ, Ding Y, Farrugia MA, et al. The endoplasmic reticulum acetyltransferases ATase1/NAT8B and ATase2/NAT8 are differentially regulated to adjust engagement of the secretory pathway. J Neurochem. 2020;e14958. DOI:10.1111/jnc.14958.
   Google Scholar
• Soreq H, Ben-Aziz R, Prody CA, et al. Molecular cloning and construction of the coding region for human acetylcholinesterase reveals a G+C-rich attenuating structure. Proc Nat Acad Sci. 1990;87(24):9688–9692.
   Google Scholar
• Xie HQ, Liang D, Leung KW, et al. Targeting acetylcholinesterase to membrane rafts: a function mediated by the proline-rich membrane anchor (PRiMA) in neurons. J Biol Chem. 2010;285(15):11537–11546.
   Google Scholar
• Karpel R, Ben Aziz-Alova R, Sternfeld M, et al. Expression of three alternative acetylcholinesterase messenger RNAs in human tumor cell lines of different tissue origins. Exp Cell Res. 1994;210(2):268–277.
   Google Scholar
• Ehrlich G, Viegas-Pequignot E, Ginzberg D, et al. Mapping the human acetylcholinesterase gene to chromosome 7q22 by fluorescent in situ hybridization coupled with selective PCR amplification from a somatic hybrid cell panel and chromosome-sorted DNA libraries. Genomics. 1992;13(4):1192–1197.
   Google Scholar
• Santos SCR, Vala I, Miguel C, et al. Expression and subcellular localization of a novel nuclear acetylcholinesterase protein. J Biol Chem. 2007;282(35):25597–25603.
   Google Scholar
• Shapira M, Tur-Kaspa I, Bosgraaf L, et al. A transcription-activating polymorphism in the ACHE promoter associated with acute sensitivity to anti-acetylcholinesterases. Hum Mol Genet. 2000;9(9):1273–1281.
   Google Scholar
• Kuhl DE, Koeppe RA, Minoshima S, et al. In vivo mapping of cerebral acetylcholinesterase activity in aging and Alzheimer’s disease. Neurology. 1999;52(4):691–699.
   Google Scholar
• Hicks DA, Makova NZ, Gough M, et al. The amyloid precursor protein represses expression of acetylcholinesterase in neuronal cell lines. J Biol Chem. 2013;288(36):26039–26051.
   Google Scholar
• Beeri R, Le Novère N, Mervis R, et al. Enhanced hemicholinium binding and attenuated dendrite branching in cognitively impaired acetylcholinesterase-transgenic mice. J Neurochem. 1997;69(6):2441–2451.
   Google Scholar
• Gaughan G, Park H, Priddle J, et al. Refinement of the localization of human butyrylcholinesterase to chromosome 3q26.1-q26.2 using a PCR-derived probe. Genomics. 1991;11(2):455–458.
   Google Scholar
• Garcia DF, Oliviera TG, Molfetta GA, et al. Biochemical and genetic analysis of butyrylcholinesterase (BChE) in a family, due to prolonged neuromuscular blockade after the use of succinylcholine. Genet Molec Biol. 2011;34(1):40–44.
   Google Scholar
• Delacour H, Lushchekina S, Mabboux I, et al. Characterization of a novel butyrylcholinesterase point mutation (p.Ala34Val), ‘silent’ with mivacurium. Biochem Pharmacol. 2014;92(3):476–483.
   Google Scholar
• Lockridge O. Review of human butyrylcholinesterase structure, function, genetic variants, history of use in the clinic, and potential therapeutic uses. Pharm Ther. 2015;148:34–46.
   Google Scholar
• Kalow W, Staron N. On distribution and inheritance of atypical forms of human serum cholinesterase, as indicated by dibucaine numbers. Canad J Biochem Physiol. 1957;35(1):1305–1320.
   Google Scholar
• Bartels CF, James K, La Du BN. DNA mutations associated with the human butyrylcholinesterase J-variant. Am J Hum Genet. 1992;50(5):1104–1114.
   Google Scholar
• Rubinstein HM, Dietz AA, Lubrano T. E1(k), another quantitative variant at cholinesterase locus 1. J Med Genet. 1978;15(1):27–29.
   Google Scholar
• Whittaker M, Britten JJ. Recognition of two new phenotypes segregating the E1k Allele For Plasma Cholinesterase. Hum Hered. 1988;38(4):233–239.
   Google Scholar
• Evans RT, Wardell J. On the identification and frequency of the J and K cholinesterase phenotypes in a caucasian population. J Med Genet. 1984;21(2):99–102.
   Google Scholar
• Lehmann DJ, Johnston C, Smith AD. Synergy between the genes for butyrylcholinesterase K variant and apolipoprotein E4 in late-onset confirmed Alzheimer’s disease. Hum Mol Genet. 1997;6(11):1933–1936.
   Google Scholar
• Wiebusch H, Poirier J, Sevigny P, et al. Further evidence for a synergistic association between APOE-4 and BCHE -K in confirmed Alzheimer’s disease. Hum Genet. 1999;104(2):158–163.
   Google Scholar
• McIlroy SP, Crawford VLS, Dynan KB, et al. Butyrylcholinesterase K variant is genetically associated with late onset Alzheimer’s disease in Northern Ireland. J Med Genet. 2000;37(3):182–185.
   Google Scholar
• O’Brien KK, Saxby BK, Ballard CG, et al. Regulation of attention and response to therapy in dementia by butyrylcholinesterase. Pharmacogenetics. 2003;13(4):231–239.
   Google Scholar
• Mikami LR, Wieseler S, Souza RL, et al. Expression of three naturally occurring genetic variants (G75R, E90D, I99M) of the BCHE gene of human butyrylcholinesterase. Pharmacogenet Genomics. 2007;17(9):681–685.
   Google Scholar
• Lando G, Mosca A, Bonora R, et al. Frequency of butyrylcholinesterase gene mutations in individuals with abnormal inhibition numbers: an Italian-population study. Pharmacogenetics. 2003;13(5):265–270.
   Google Scholar
• Lane R, Feldman HH, Meyer J, et al. Synergistic effect of apolipoprotein E epsilon4 and butyrylcholinesterase K-variant on progression from mild cognitive impairment to Alzheimer’s disease. Pharmacogenet Genomics. 2008;18(4):289–928.
   Google Scholar
• Darreh-Shori T, Siawesh M, Mousavi M, et al. Apolipoprotein ε4 modulates phenotype of butyrylcholinesterase in CSF of patients with Alzheimer’s disease. J Alzheimers Dis. 2012;28(2):443–458.
   Google Scholar
• Apparsundaram S, Ferguson SM, George AL, et al. Molecular cloning of a human, hemicholinium-3-sensitive choline transporter. Biochem Biophys Res Commun. 2000;276(3):862–867.
   Google Scholar
• Okuda T, Haga T. Functional characterization of the human high-affinity choline transporter 1. FEBS Lett. 2000;484(2):92–97.
   Google Scholar
• Okuda T, Okamura M, Kaitsuka C, et al. Single nucleotide polymorphism of the human high affinity choline transporter alters transport rate. J Biol Chem. 2002;277(47):45315–45322.
   Google Scholar
• Barwick KES, Wright J, Al-Turki S, et al. Defective presynaptic choline transport underlies hereditary motor neuropathy. Am J Hum Genet. 2012;91(6):1103–1107.
   Google Scholar
• Bauche S, O’Regan S, Azuma Y, et al. Impaired presynaptic high-affinity choline transporter causes a congenital myasthenic syndrome with episodic apnea. Am J Hum Genet. 2016;99(3):753–761.
   Google Scholar
• Lockman PR, Allen DD. The transport of choline. Drug Dev Ind Pharm. 2002;28(7):749–771.
   Google Scholar
• Hassel B, Solyga V, Lossius A. High-affinity choline uptake and acetylcholine-metabolizing enzymes in CNS white matter. a quantitative study. Neurochem Int. 2008;53(6–8):193–198.
   Google Scholar
• Kristofiková Z, Kopecký V, Hofbauerová K, et al. Complex of amyloid beta peptides with 24-hydroxycholesterol and its effect on hemicholinium-3 sensitive carriers. Neurochem Res. 2008;33(3):412–421.
   Google Scholar
• Bissette G, Seidler FJ, Nemeroff CB, et al. High affinity choline transporter status in Alzheimer’s disease tissue from rapid autopsy. Ann N Y Acad Sci. 1996;777(1):197–204.
   Google Scholar
• Slotkin TA, Nemeroff CB, Bissette G, et al. Overexpression of the high affinity choline transporter in cortical regions affected by Alzheimer’s diseaseEvidence from rapid autopsy studies. J Clin Invest.. 1994;94(2):696–702.
   Google Scholar
• Cuddy LK, Seah C, Pasternak SH, et al. Amino-terminal β-amyloid antibody blocks β-amyloid-mediated inhibition of the high-affinity choline transporter CHT. Front Mol Neurosci. 2017;10:361.
   Google Scholar
• Wang B, Yang L, Wang Z, et al. Amyolid precursor protein mediates presynaptic localization and activity of the high-affinity choline transporter. Proc Natl Acad Sci USA. 2007;104(35):14140–14145.
   Google Scholar
• Cuddy LK, Seah C, Pasternak SH, et al. Differential regulation of the high-affinity choline transporter by wild-type and Swedish mutant amyloid precursor protein. J Neurochem. 2015;134(4):769–782.
   Google Scholar
• Payette DJ, Xie J, Guo Q. Reduction in CHT1-mediated choline uptake in primary neurons from presenilin-1 M146V mutant knock-in mice. Brain Res. 2007;1135(1):12–21.
   Google Scholar
• Del Pino J, Moyano P, Díaz GG, et al. Primary hippocampal neuronal cell death induction after acute and repeated paraquat exposures mediated by AChE variants alteration and cholinergic and glutamatergic transmission disruption. Toxicology. 2017;390:88–99.
   Google Scholar
• Del Pino J, Moyano P, Anadon MJ, et al. Acute and long-term exposure to chlorpyrifos induces cell death of basal forebrain cholinergic neurons through AChE variants alteration. Toxicology. 2015;336:1–9.
   Google Scholar
• Chen BH, Park JH, Kim DW, et al. Melatonin improves cognitive deficits via restoration of cholinergic dysfunction in a mouse model of scopolamine-induced Amnesia. ACS Chem Neurosci. 2018;9(8):2016–2024.
   Google Scholar
• Kristofikova Z, Ricny J, Soukup O, et al. Inhibitors of Acetylcholinesterase derived from 7-methoxytacrine and their effects on the choline transporter CHT1. Dement Geriatr Cogn Disord. 2017;43(1–2):45–58.
   Google Scholar
• Volpicelli-Daley LA, Hrabovska A, Duysen EG, et al. Altered striatal function and muscarinic cholinergic receptors in acetylcholinesterase knockout mice. Mol Pharmacol. 2003;64(6):1309–1316.
   Google Scholar
• Yamada H, Imajoh-Ohmi S, Haga T. The high-affinity choline transporter CHT1 is regulated by the ubiquitin ligase Nedd4-2. Biomed Res. 2012;33(1):1–8.
   Google Scholar
• Fishwick KJ, Rylett RJ, Kanzaki M. Insulin regulates the activity of the high-affinity choline transporter CHT. PLoS One. 2015;10(7):e0132934.
   Google Scholar
• Tomassoni D, Catalani A, Cinque C, et al. Effects of cholinergic enhancing drugs on cholinergic transporters in the brain and peripheral blood lymphocytes of spontaneously hypertensive rats. Curr Alzheimer Res. 2012;9(1):120–127.
   Google Scholar
• Luo D, Chen L, Yu B. Inhibition of the high affinity choline transporter enhances hyperalgesia in a rat model of chronic pancreatitis. Biochem Biophys Res Commun. 2017;488(1):204–210.
   Google Scholar
• Ennis EA, Wright J, Retzlaff CL, et al. Identification and characterization of ML352: a novel, noncompetitive inhibitor of the presynaptic choline transporter. ACS Chem Neurosci. 2015;6(3):417–427.
   Google Scholar
• Kang YS, Lee KE, Lee NY, et al. Donepezil, tacrine and alpha-phenyl-n-tert-butyl nitrone (PBN) inhibit choline transport by conditionally immortalized rat brain capillary endothelial cell lines (TR-BBB). Arch Pharm Res. 2005;28(4):443–450.
   Google Scholar
• O’Grady GL, Verschuuren C, Yuen M, et al. Variants in SLC18A3, vesicular acetylcholine transporter, cause congenital myasthenic syndrome. Neurology. 2016;87(14):1442–1448.
   Google Scholar
• Wang Y, Zhou Z, Tan H, et al. Nitrosylation of Vesicular Transporters in Brain of Amyloid Precursor Protein/Presenilin 1 Double Transgenic Mice. J Alzheimers Dis. 2017;55(4):1683–1692.
   Google Scholar
• Nagy PM, Aubert I. Overexpression of the vesicular acetylcholine transporter increased acetylcholine release in the hippocampus. Neuroscience. 2012;218:1–11.
   Google Scholar
• Nagy PM, Aubert I. B6eGFPChAT mice overexpressing the vesicular acetylcholine transporter exhibit spontaneous hypoactivity and enhanced exploration in novel environments. Brain Behav. 2013;3(4):367–383.
   Google Scholar
• de Castro BM, Pereira GS, Magalhães V, et al. Reduced expression of the vesicular acetylcholine transporter causes learning deficits in mice. Genes Brain Behav. 2009;8(1):23–35.
   Google Scholar
• Kolisnyk B, Al-Onaizi MA, Xu J, et al. Cholinergic regulation of hnRNPA2/B1 translation by M1 muscarinic receptors. J Neurosci. 2016;36(23):6287–6296.
   Google Scholar
• Hu L, Wong TP, Côté SL, et al. The impact of Abeta-plaques on cortical cholinergic and non-cholinergic presynaptic boutons in alzheimer’s disease-like transgenic mice. Neuroscience. 2003;121(2):421–432.
   Google Scholar
• Dolejší E, Liraz O, Rudajev V, et al. Apolipoprotein E4 reduces evoked hippocampal acetylcholine release in adult mice. J Neurochem. 2016;136(3):503–509.
   Google Scholar
• Mazère J, Prunier C, Barret O, et al. In vivo SPECT imaging of vesicular acetylcholine transporter using [(123)I]-IBVM in early Alzheimer’s disease. Neuroimage. 2008;40(1):280–288.
   Google Scholar
• Efange SM, Garland EM, Staley JK, et al. Vesicular acetylcholine transporter density and Alzheimer’s disease. Neurobiol Aging. 1997;18(4):407–413.
   Google Scholar
• Gilmor ML, Erickson JD, Varoqui H, et al. Preservation of nucleus basalis neurons containing choline acetyltransferase and the vesicular acetylcholine transporter in the elderly with mild cognitive impairment and early Alzheimer’s disease. J Comp Neurol. 1999;411(4):693–704.
   Google Scholar
• Parent MJ, Bedard MA, Aliaga A, et al. Cholinergic depletion in Alzheimer’s disease shown by [(18) F]FEOBV autoradiography. Int J Mol Imaging. 2013;2013:205045.
   Google Scholar
• Kovac M, Mavel S, Deuther-Conrad W, et al. 3D QSAR study, synthesis, and in vitro evaluation of (+)-5-FBVM as potential PET radioligand for the vesicular acetylcholine transporter (VAChT). Bioorg Med Chem. 2010;18(21):7659–7667.
   Google Scholar
• Giboureau N, Som IM, Boucher-Arnold A, et al. PET radioligands for the vesicular acetylcholine transporter (VAChT). Curr Top Med Chem. 2010;10(15):1569–1583.
   Google Scholar
• Albin RL, Bohnen NI, Muller MLTM, et al. Regional vesicular acetylcholine transporter distribution in human brain: A [18 F]fluoroethoxybenzovesamicol positron emission tomography study. J Comp Neurol. 2018;526(17):2884–2897.
   Google Scholar
• Aghourian M, Legault-Denis C, Soucy JP, et al. Quantification of brain cholinergic denervation in Alzheimer’s disease using PET imaging with [18F]-FEOBV. Mol Psychiatry. 2017;22(11):1531–1538.
   Google Scholar
• Higashida H, Yokoyama S, Tsuji C, et al. Neurotransmitter release: vacuolar ATPase V0 sector c-subunits in possible gene or cell therapies for Parkinson’s, Alzheimer’s, and psychiatric diseases. J Physiol Sci. 2017;67(1):11–17.
   Google Scholar
• Wallace TL, Bertrand D. Importance of the nicotinic acetylcholine receptor system in the prefrontal cortex. Biochem Pharmacol. 2013;85(12):1713–1720.
   Google Scholar
• Weng PH, Chen JH, Chen TF, et al. CHRNA7 polymorphisms and dementia risk: interactions with apolipoprotein ε4 and cigarette smoking. Sci Rep. 2016;6(1):27231.
   Google Scholar
• Russo P, Kisialiou A, Moroni R, et al. Effect of genetic polymorphisms (SNPs) in CHRNA7 gene on response to acetylcholinesterase inhibitors (AChEI) in patients with Alzheimer’s disease. Curr Drug Targets. 2017;18(10):1179–1190.
   Google Scholar
• Yang WN, Ma KG, Chen XL, et al. Mitogen-activated protein kinase signaling pathways are involved in regulating α7 nicotinic acetylcholine receptor-mediated amyloid-β uptake in SH-SY5Y cells. Neuroscience. 2014;278:276–290.
   Google Scholar
• Ma KG, Qian YH. Alpha 7 nicotinic acetylcholine receptor and its effects on Alzheimer’s disease. Neuropeptides. 2019;73:96–106.
   Google Scholar
• Sinkus ML, Graw S, Freedman R, et al. The human CHRNA7 and CHRFAM7A genes: A review of the genetics, regulation, and function. Neuropharmacology. 2015;96(Pt B):274–288.
   Google Scholar
• Jiang Y, Yuan H, Huang L, et al. Global proteomic profiling of the uniquely human CHRFAM7A gene in transgenic mouse brain. Gene. 2019;714:143996.
   Google Scholar
• Liu Q, Xie X, Emadi S, et al. A novel nicotinic mechanism underlies β-amyloid-induced neurotoxicity. Neuropharmacology. 2015;97:457–463.
   Google Scholar
• Sadigh-Eteghad S, Talebi M, Mahmoudi J, et al. Selective activation of α7 nicotinic acetylcholine receptor by PHA-543613 improves Aβ25-35-mediated cognitive deficits in mice. Neuroscience. 2015;298:81–93.
   Google Scholar
• Li L, Liu Z, Jiang YY, et al. Acetylcholine suppresses microglial inflammatory response via α7nAChR to protect hippocampal neurons. J Integr Neurosci. 2019;18(1):51–56.
   Google Scholar
• Chang KW, Zong HF, Ma KG, et al. Activation of α7 nicotinic acetylcholine receptor alleviates Aβ1-42-induced neurotoxicity via downregulation of p38 and JNK MAPK signaling pathways. Neurochem Int. 2018;120:238–250.
   Google Scholar
• Shi S, Liang D, Bao M, et al. Gx-50 inhibits neuroinflammation via α7 nAChR activation of the JAK2/STAT3 and PI3K/AKT pathways. J Alzheimers Dis. 2016;50(3):859–871.
   Google Scholar
• Yin J, Chen W, Yang H, et al. Chrna7 deficient mice manifest no consistent neuropsychiatric and behavioral phenotypes. Sci Rep. 2017;7(1):39941.
   Google Scholar
• Schaaf CP. Nicotinic acetylcholine receptors in human genetic disease. Genet Med. 2014;16(9):649–656.
   Google Scholar
• Darreh-Shori T, Rezaeianyazdi S, Lana E, et al. Increased active OMI/HTRA2 serine protease displays a positive correlation with cholinergic alterations in the Alzheimer’s disease brain. Mol Neurobiol. 2019;56(7):4601–4619.
   Google Scholar
• McKeever PM, Kim T, Hesketh AR, et al. Cholinergic neuron gene expression differences captured by translational profiling in a mouse model of Alzheimer’s disease. Neurobiol Aging. 2017;57:104–119.
   Google Scholar
• Kolisnyk B, Al-Onaizi M, Soreq L, et al. Cholinergic surveillance over hippocampal RNA metabolism and Alzheimer’s-like pathology. Cereb Cortex. 2017;27(7):3553–3567.
   Google Scholar
• Cacabelos R, Tellado I, Cacabelos P. The epigenetic machinery in the life cycle and pharmacoepigenetics. In: Cacabelos R, editor. Pharmacoepigenetics. Oxford (UK): Academic Press/Elsevier; 2019. p. 1–100.
   Google Scholar
• Cacabelos R, Carril JC, Sanmartín A, et al. Pharmacoepigenetic processors: epigenetic drugs, drug resistance, toxicoepigenetics, and nutriepigenetics. In: Cacabelos R, editor. Pharmacoepigenetics. Oxford (UK): Academic Press/Elsevier; 2019. p. 191–424.
   Google Scholar
• Apostolova LG, Risacher SL, Duran T, et al. Alzheimer’s disease neuroimaging initiative. associations of the Top 20 Alzheimer disease risk variants with brain amyloidosis. JAMA Neurol. 2018;75(3):328–341.
   Google Scholar
• Cacabelos R, Meyyazhagan A, Carril JC, et al. Pharmacogenetics of vascular risk factors in Alzheimer’s disease. J Pers Med. 2018;8(1):E3.
   Google Scholar
• Cacabelos R, Torrellas C. Epigenetics of aging and Alzheimer’s disease: implications for pharmacogenomics and drug response. Int J Mol Sci. 2015;16(12):30483–30543.
   Google Scholar
• Cacabelos R. Pleiotropy and promiscuity in pharmacogenomics for the treatment of Alzheimer’s disease and related risk factors. Future Neurol. 2018;13(2):2.
   Google Scholar
• Cacabelos R, Torrellas C. Epigenetic drug discovery for Alzheimer’s disease. Expert Opin Drug Discov. 2014;9(9):1059–1086.
   Google Scholar
• Cacabelos R, Torrellas C. Pharmacogenomics of antidepressants. HSOA J Psychiatry Depression Anxiety. 2015;1(1):001.
   Google Scholar
• Foraker J, Millard SP, Leong L. The APOE gene is differentially methylated in Alzheimer’s disease. J Alzheimers Dis. 2015;48(3):745–755.
   Google Scholar
• Liu J, Zhao W, Ware EB, et al. DNA methylation in the APOE genomic region is associated with cognitive function in African Americans. BMC Med Genomics. 2018;11(1):43.
   Google Scholar
• Dresselhaus E, Duerr JM, Vincent F, et al. Class I HDAC inhibition is a novel pathway for regulating astrocytic apoE secretion. PLoS One. 2018;13(3):e0194661.
   Google Scholar
• Shao Y, Shaw M, Todd K, et al. DNA methylation of TOMM40-APOE-APOC2 in Alzheimer’s disease. J Hum Genet. 2018;63(4):459–471.
   Google Scholar
• Ghanbari M, Ikram MA, de Looper HWJ, et al. Genome-wide identification of microRNA-related variants associated with risk of Alzheimer’s disease. Sci Rep. 2016;6(1):28387.
   Google Scholar
• Dorszewska J, Prendecki M, Oczkowska A, et al. Molecular basis of familial and sporadic Alzheimer’s disease. Curr Alzheimer Res. 2016;13(9):952–963.
   Google Scholar
• Driscoll I, Snively BM, Espeland MA, et al. A candidate gene study of risk for dementia in older, postmenopausal women: results from the women’s health initiative memory study. Int J Geriatr Psychiatry. 2019;34(5):692–699.
   Google Scholar
• Bi R, Zhang W, Zhang DF, et al. Genetic association of the cytochrome c oxidase-related genes with Alzheimer’s disease in Han Chinese. Neuropsychopharmacology. 2018;43(11):2264–2276.
   Google Scholar
• Holstege H, van der Lee S, Hulsman M, et al. Characterization of pathogenic SORL1 genetic variants for association with Alzheimer’s disease: a clinical interpretation strategy. Eur J Hum Genet. 2017;25(8):973–981.
   Google Scholar
• Lefterov I, Wolfe CM, Fitz NF, et al. APOE2 orchestrated differences in transcriptomic and lipidomic profiles of postmortem AD brain. Alzheimers Res Ther. 2019;11(1):113.
   Google Scholar
• Zhou L, Li HY, Wang JH, et al. Correlation of gene polymorphisms of CD36 and ApoE with susceptibility of Alzheimer disease: a case-control study. Medicine (Baltimore). 2018;97(38):e12470.
   Google Scholar
• Broer L, Buchman AS, Deelen J, et al. GWAS of longevity in CHARGE consortium confirms APOE and FOXO3 candidacy. J Gerontol A Biol Sci Med Sci. 2015;70(1):110–118.
   Google Scholar
• Lyall DM, Royle NA, Harris SE, et al. Alzheimer’s disease susceptibility genes APOE and TOMM40, and hippocampal volumes in the Lothian birth cohort 1936. PLoS One. 2013;8(11):e80513.
   Google Scholar
• Reitz C, Jun G, Naj A, et al. Variants in the ATP-binding cassette transporter (ABCA7), apolipoprotein E ϵ4, and the risk of late-onset Alzheimer disease in African Americans. JAMA. 2013;309(14):1483–1492.
   Google Scholar
• Davies G, Harris SE, Reynolds CA, et al. A genome-wide association study implicates the APOE locus in nonpathological cognitive ageing. Mol Psychiatry. 2014;19(1):76–87.
   Google Scholar
• Bronfman FC, Tesseur I, Hofker MH, et al. No evidence for cholinergic problems in apolipoprotein E knockout and apolipoprotein E4 transgenic mice. Neuroscience. 2000;97(3):411–418.
   Google Scholar
• Lee WJ, Liao YC, Wang YF, et al. Summative effects of vascular risk factors on the progression of Alzheimer disease. J Am Geriatr Soc. 2020;68(1):129–136.
   Google Scholar
• Vogelgesang S, Cascorbi I, Schroeder E, et al. Deposition of Alzheimer’s beta-amyloid is inversely correlated with P-glycoprotein expression in the brains of elderly non-demented humans. Pharmacogenetics. 2002;12(7):535–541.
   Google Scholar
• Szablewski L. Glucose transporters in brain: in health and in Alzheimer’s disease. J Alzheimers Dis. 2017;55(4):1307–1320.
   Google Scholar
• Cacabelos R, López-Muñoz F. The ABCB1 transporter in Alzheimer’s disease. Clin Exp Pharmacol. 2014;4(2):e128.
   Google Scholar
• Cacabelos R, Cacabelos P, Carril JC. Epigenetics and pharmacoepigenetics of age-related neurodegenerative disorders. In: Cacabelos R, editor. Pharmacoepigenetics. Oxford (UK): Academic Press/Elsevier; 2019. p. 903–950.
   Google Scholar
• Berg CN, Sinha N, Gluck MA. The Effects of APOE and ABCA7 on cognitive function and Alzheimer’s disease risk in African Americans: a focused mini review. Front Hum Neurosci. 2019;13:38.
   Google Scholar
• Pereira CD, Martins F, Wiltfang J, et al. ABC transporters are key players in Alzheimer’s disease. J Alzheimers Dis. 2018;61(2):463–485.
   Google Scholar
• Marquez B, Van Bambeke F. ABC multidrug transporters: target for modulation of drug pharmacokinetics and drug-drug interactions. Curr Drug Targets. 2011;12(5):600–620.
   Google Scholar
• Haufroid V. Genetic polymorphisms of ATP-binding cassette transporters ABCB1 and ABCC2 and their impact on drug disposition. Curr Drug Targets. 2011;12(5):631–646.
   Google Scholar
• Chai AB, Leung GKF, Callaghan R, et al. P-glycoprotein: a role in the export of amyloid-β in Alzheimer’s disease? Febs J. 2020;287(4):612–625.
   Google Scholar
• Elali A, Rivest S. The role of ABCB1 and ABCA1 in beta-amyloid clearance at the neurovascular unit in Alzheimer’s disease. Front Physiol. 2013;4:45.
   Google Scholar
• Alharbi HA, Alcorn J, Al-Mousa A, et al. Toxicokinetics and toxicodynamics of chlorpyrifos is altered in embryos of Japanese medaka exposed to oil sands process-affected water: evidence for inhibition of P-glycoprotein. J Appl Toxicol. 2017;37(5):591–601.
   Google Scholar
• Bruckmann S, Brenn A, Grube M, et al. Lack of P-glycoprotein results in impairment of removal of beta-amyloid and increased intraparenchymal cerebral amyloid angiopathy after active immunization in a transgenic mouse model of Alzheimer’s disease. Curr Alzheimer Res. 2017;14(6):656–667.
   Google Scholar
• Fehér Á, Juhász A, Pákáski M, et al. ABCB1 C3435T polymorphism influences the risk for Alzheimer’s disease. J Mol Neurosci. 2014;54(4):826–829.
   Google Scholar
• Alam MA, Datta PK. Epigenetic regulation of excitatory amino acid transporter 2 in neurological disorders. Front Pharmacol. 2019;10:1510.
   Google Scholar
• Sharma A, Kazim SF, Larson CS, et al. Divergent roles of astrocytic versus neuronal EAAT2 deficiency on cognition and overlap with aging and Alzheimer’s molecular signatures. Proc Natl Acad Sci USA. 2019;116(43):21800–21811.
   Google Scholar
• Pang R, Wang X, Du Z, et al. The distribution and density of monocarboxylate transporter 2 in cerebral cortex, hippocampus and cerebellum of wild-type mice. J Anat. 2020;236(2):370–377.
   Google Scholar
• Shubbar MH, Penny JI. Effect of amyloid beta on ATP-binding cassette transporter expression and activity in porcine brain microvascular endothelial cells. Biochim Biophys Acta Gen Subj. 2018;1862(10):2314–2322.
   Google Scholar
• Vauthier V, Housset C, Falguières T. Targeted pharmacotherapies for defective ABC transporters. Biochem Pharmacol. 2017;136:1–11.
   Google Scholar
• Fan J, Zareyan S, Zhao W, et al. Identification of a Chrysanthemic Ester as an Apolipoprotein E Inducer in astrocytes. PLoS One. 2016;11(9):e0162384.
   Google Scholar
• Padala AK, Wani A, Vishwakarma RA, et al. Functional induction of P-glycoprotein efflux pump by phenyl benzenesulfonamides: synthesis and biological evaluation of T0901317 analogs. Eur J Med Chem. 2016;122:744–755.
   Google Scholar
• Li DD, Zhang YH, Zhang W, et al. Meta-analysis of randomized controlled trials on the efficacy and safety of Donepezil, Galantamine, Rivastigmine, and Memantine for the treatment of Alzheimer’s disease. Front Neurosci. 2019;13:472.
   Google Scholar
• Dekker MJHJ, Bouvy JC, O’Rourke D, et al. Alignment of european regulatory and health technology assessments: a review of licensed products for Alzheimer’s disease. Front Med. 2019;6:73.
   Google Scholar
• Cacabelos R, Llovo R, Fraile C, et al. Pharmacogenetic aspects of therapy with cholinesterase inhibitors: the role of CYP2D6 in Alzheimer’s disease pharmacogenetics. Curr Alzheimer Res. 2007;4(4):479–500.
   Google Scholar
• Cacabelos R. Donepezil in Alzheimer’s disease: from conventional trials to pharmacogenetics. Neuropsychiatr Dis Treat. 2007;3(3):303–333.
   Google Scholar
• Cacabelos R, Takeda M, Winblad B. The glutamatergic system and neurodegeneration in dementia: preventive strategies in Alzheimer’s disease. Int J Geriat Psychiatry. 1999;14(1):3–47.
   Google Scholar
• Sumirtanurdin R, Thalib AY, Cantona K, et al. Effect of genetic polymorphisms on Alzheimer’s disease treatment outcomes: an update. Clin Interv Aging. 2019;14:631–642.
   Google Scholar
• Ma SL, Tang NLS, Wat KHY, et al. Effect of CYP2D6 and CYP3A4 genotypes on the efficacy of cholinesterase inhibitors in Southern Chinese patients with Alzheimer’s disease. Am J Alzheimers Dis Other Demen. 2019;34(5):302–307.
   Google Scholar
• Zhang N, Gordon ML. Clinical efficacy and safety of donepezil in the treatment of Alzheimer’s disease in Chinese patients. Clin Interv Aging. 2018;13:1963–1970.
   Google Scholar
• Zhao Q, Brett M, Van Osselaer N, et al. Galantamine pharmacokinetics, safety, and tolerability profiles are similar in healthy Caucasian and Japanese subjects. J Clin Pharmacol. 2002;42(9):1002–1010.
   Google Scholar
• Farlow MR. Clinical pharmacokinetics of galantamine. Clin Pharmacokinet. 2003;42(15):1383–1392.
   Google Scholar
• Clarke JA, Cutler M, Gong I, et al. Cytochrome P450 2D6 phenotyping in an elderly population with dementia and response to galantamine in dementia: a pilot study. Am J Geriatr Pharmacother. 2011;9(4):224–233.
   Google Scholar
• Hays CC, Zlatar ZZ, Meloy MJ, et al. Anterior cingulate structure and perfusion is associated with cerebrospinal fluid tau among cognitively normal older adult APOEɛ4 carriers. J Alzheimers Dis. 2020;73(1):87–101.
   Google Scholar
• Weintraub S, Teylan M, Rader B, et al. APOE is a correlate of phenotypic heterogeneity in Alzheimer disease in a national cohort. Neurology. 2020;94(6):e607–e612.
   Google Scholar
• Suwa A, Nishida K, Utsunomiya K, et al. Neuropsychological evaluation and cerebral blood flow effects of apolipoprotein E4 in Alzheimer’s disease patients after one year of treatment: an exploratory study. Dement Geriatr Cogn Dis Extra. 2015;5(3):414–423.
   Google Scholar
• Cacabelos R. Molecular pathology and pharmacogenomics in Alzheimer’s disease: polygenic-related effects of multifactorial treatments on cognition, anxiety and depression. Methods Find Exp Clin Pharmacol. 2007;29:1–91.
   Google Scholar
• Cacabelos R, Martínez R, Fernández-Novoa L, et al. Genomics of dementia: APOE- and CYP2D6-related pharmacogenetics. Int J Alzheimers Dis. 2012;518901. DOI:10.1155/2012/518901.
   Google Scholar
• Cheng YC, Huang YC, Liu HC. Effect of Apolipoprotein E ɛ4 carrier status on cognitive response to acetylcholinesterase inhibitors in patients with Alzheimer’s Disease: a systematic review and meta-analysis. Dement Geriatr Cogn Disord. 2018;45(5–6):335–352.
   Google Scholar
• Noetzli M, Eap CB. Pharmacodynamic, pharmacokinetic and pharmacogenetic aspects of drugs used in the treatment of Alzheimer’s disease. Clin Pharmacokinet. 2013;52(4):225–241.
   Google Scholar
• Cacabelos R, Goldgaber D, Vostrov A, et al. APOE-TOMM40 in the Pharmacogenomics of demetia. J. Pharmacogenomics Pharmacoproteomics.. 2014;5:135.
   Google Scholar
• Wattmo C, Blennow K, Hansson O. Cerebro-spinal fluid biomarker levels: phosphorylated tau (T) and total tau (N) as markers for rate of progression in Alzheimer’s disease. BMC Neurol. 2020;20(1):10.
   Google Scholar
• Yoon H, Myung W, Lim SW, et al. Association of the choline acetyltransferase gene with responsiveness to acetylcholinesterase inhibitors in Alzheimer’s disease. Pharmacopsychiatry. 2015;48(3):111–117.
   Google Scholar
• Yuan H, Xia Q, Ling K, et al. Association of choline acetyltransferase gene polymorphisms (SNPs rs868750G/A, rs1880676G/A, rs2177369G/A and rs3810950G/A) with Alzheimer’s disease risk: a meta-analysis. PLoS One. 2016;11(7): e0159022.
   Google Scholar
• Harold D, Macgregor S, Patterson CE, et al. A single nucleotide polymorphism in CHAT influences response to acetylcholinesterase inhibitors in Alzheimer’s disease. Pharmacogenet Genomics. 2006;16(2):75–77.
   Google Scholar
• Clarelli F, Mascia E, Santangelo R, et al. CHRNA7 gene and response to cholinesterase inhibitors in an italian cohort of Alzheimer’s disease patients. J Alzheimers Dis. 2016;52(4):1203–1208.
   Google Scholar
• Martinelli-Boneschi F, Giacalone G, Magnani G, et al. Pharmacogenomics in Alzheimer’s disease: a genome-wide association study of response to cholinesterase inhibitors. Neurobiol Aging. 2013;34(6):1711.e7-1711.e13.
   Google Scholar
• Paroni G, Seripa D, Fontana A, et al. FOXO1 locus and acetylcholinesterase inhibitors in elderly patients with Alzheimer’s disease. Clin Interv Aging. 2014;9:1783–1791.
   Google Scholar
• Klimkowicz-Mrowiec A, Marona M, Spisak K, et al. Paraoxonase 1 gene polymorphisms do not influence the response to treatment in Alzheimer’s disease. Dement Geriatr Cogn Disord. 2011;32(1):26–31.
   Google Scholar
• Campbell NL, Skaar TC, Perkins AJ, et al. Characterization of hepatic enzyme activity in older adults with dementia: potential impact on personalizing pharmacotherapy. Clin Interv Aging. 2015;10:269–275.
   Google Scholar
• Birks JS, Harvey RJ. Donepezil for dementia due to Alzheimer’s disease. Cochrane Database Syst Rev. 2018;6:CD001190.
   Google Scholar
• Brewster JT, Dell’Acqua S, Thach DQ, et al. Classics in chemical Neuroscience: donepezil. ACS Chem Neurosci. 2019;10(1):155–167.
   Google Scholar
• Noetzli M, Guidi M, Ebbing K, et al. Population pharmacokinetic approach to evaluate the effect of CYP2D6, CYP3A, ABCB1, POR and NR1I2 genotypes on donepezil clearance. Br J Clin Pharmacol. 2014;78(1):135–144.
   Google Scholar
• Haug KH, Bogen IL, Osmundsen H, et al. Effects on cholinergic markers in rat brain and blood after short and prolonged administration of donepezil. Neurochem Res. 2005;30(12):1511–1520.
   Google Scholar
• Ginestet L, Ferrario JE, Raisman-Vozari R, et al. Donepezil induces a cholinergic sprouting in basocortical degeneration. J Neurochem. 2007;102(2):434–440.
   Google Scholar
• Kimura M, Akasofu S, Ogura H, et al. Protective effect of donepezil against Abeta(1-40) neurotoxicity in rat septal neurons. Brain Res. 2005;1047(1):72–84.
   Google Scholar
• Pilotto A, Franceschi M, D’Onofrio G, et al. Effect of a CYP2D6 polymorphism on the efficacy of donepezil in patients with Alzheimer disease. Neurology. 2009;73(10):761–767.
   Google Scholar
• Seripa D, Bizzarro A, Pilotto A, et al. Role of cytochrome P4502D6 functional polymorphisms in the efficacy of donepezil in patients with Alzheimer’s disease. Pharmacogenet Genomics. 2011;21(4):225–230.
   Google Scholar
• Xiao T, Jiao B, Zhang W, et al. Effect of the CYP2D6 and APOE polymorphisms on the efficacy of donepezil in patients with Alzheimer’s disease: a systematic review and meta-analysis. CNS Drugs. 2016;30(10):899–907.
   Google Scholar
• Waring JF, Tang Q, Robieson WZ, et al. APOE-ɛ4 carrier status and donepezil response in patients with Alzheimer’s disease. J Alzheimers Dis. 2015;47(1):137–148.
   Google Scholar
• Albani D, Martinelli BF, Biella G, et al. Replication study to confirm the role of CYP2D6 polymorphism rs1080985 on donepezil efficacy in Alzheimer’s disease patients. J Alzheimers Dis. 2012;30(4):745–749.
   Google Scholar
• Liu M, Zhang Y, Huo YR, et al. Influence of the rs1080985 single nucleotide polymorphism of the CYP2D6 gene and APOE polymorphism on the response to donepezil treatment in patients with Alzheimer’s disease in China. Dement Geriatr Cogn Dis Extra. 2014;4(3):450–456.
   Google Scholar
• Klimkowicz-Mrowiec A, Wolkow P, Sado M, et al. Influence of rs1080985 single nucleotide polymorphism of the CYP2D6 gene on response to treatment with donepezil in patients with alzheimer’s disease. Neuropsychiatr Dis Treat. 2013;9:1029–1033.
   Google Scholar
• Choi SH, Kim SY, Na HR, et al. Effect of ApoE genotype on response to donepezil in patients with Alzheimer’s disease. Dement Geriatr Cogn Disord. 2008;25(5):445–450.
   Google Scholar
• Zhong Y, Zheng X, Miao Y, et al. Effect of CYP2D6*10 and APOE polymorphisms on the efficacy of donepezil in patients with Alzheimer’s disease. Am J Med Sci. 2013;345(3):222–226.
   Google Scholar
• Lu J, Fu J, Zhong Y, et al. The roles of apolipoprotein E3 and CYP2D6 (rs1065852) gene polymorphisms in the predictability of responses to individualized therapy with donepezil in Han Chinese patients with Alzheimer’s disease. Neurosci Lett. 2016;614:43–48.
   Google Scholar
• Yaowaluk T, Senanarong V, Limwongse C, et al. Influence of CYP2D6, CYP3A5, ABCB1, APOE polymorphisms and nongenetic factors on donepezil treatment in patients with Alzheimer’s disease and vascular dementia. Pharmgenomics Pers Med. 2019;12:209–224.
   Google Scholar
• Tiseo PJ, Perdomo CA, Friedhoff LT. Concurrent administration of donepezil HCl and ketoconazole: assessment of pharmacokinetic changes following single and multiple doses. Br J Clin Pharmacol. 1998;46(1):30–34.
   Google Scholar
• Lu J, Fu J, Zhong Y, et al. Association between ABCA1 gene polymorphisms and the therapeutic response to donepezil therapy in Han Chinese patients with Alzheimer’s disease. Brain Res Bull. 2018;140:1–4.
   Google Scholar
• Magliulo L, Dahl ML, Lombardi G, et al. Do CYP3A and ABCB1 genotypes influence the plasma concentration and clinical outcome of donepezil treatment? Eur J Clin Pharmacol. 2011;67(1):47–54.
   Google Scholar
• Kim JY, Son JY, Lee BM, et al. Aging-related Repositioned Drugs, Donepezil and Sildenafil Citrate, Increase Apoptosis of Anti-mitotic Drug-resistant KBV20C cells through different molecular mechanisms. Anticancer Res. 2018;38(9):5149–5157.
   Google Scholar
• Petersen RC, Thomas RG, Grundman M, et al., Vitamin E and donepezil for the treatment of mild cognitive impairment. N Engl J Med. 2005;352(23): 2379–2388.
   Google Scholar
• De Beaumont L, Pelleieux S, Lamarre-Théroux L, et al. Butyrylcholinesterase K and Apolipoprotein E-ɛ4 reduce the age of onset of Alzheimer’s Disease, Accelerate Cognitive Decline, and Modulate Donepezil response in mild cognitively impaired subjects. J Alzheimers Dis. 2016;54(3):913–922.
   Google Scholar
• Sokolow S, Li X, Chen L, et al. Deleterious effect of butyrylcholinesterase K-variant in Donepezil treatment of mild cognitive impairment. J Alzheimers Dis. 2017;56(1):229–237.
   Google Scholar
• Chae YJ, Lee HJ, Jeon JH, et al. Effects of donepezil on hERG potassium channels. Brain Res. 2015;1597:77–85.
   Google Scholar
• Imamura O, Arai M, Dateki M, et al. Nicotinic acetylcholine receptors mediate donepezil-induced oligodendrocyte differentiation. J Neurochem. 2015;135(6):1086–1098.
   Google Scholar
• Chang YS, Wu YH, Wang CJ, et al. Higher levels of thyroxine may predict a favorable response to donepezil treatment in patients with Alzheimer disease: a prospective, case-control study. BMC Neurosci. 2018;19(1):36.
   Google Scholar
• Borroni B, Colciaghi F, Pastorino L, et al. ApoE genotype influences the biological effect of donepezil on APP metabolism in Alzheimer disease: evidence from a peripheral model. Eur Neuropsychopharmacol. 2002;12(3):195–200.
   Google Scholar
• Takeuchi R, Shinozaki K, Nakanishi T, et al. Local drug-drug interaction of Donepezil with Cilostazol at Breast Cancer Resistance Protein (ABCG2) increases drug accumulation in heart. Drug Metab Dispos. 2016;44(1):68–74.
   Google Scholar
• Cummings J, Lai TJ, Hemrungrojn S, et al. Role of Donepezil in the management of Neuropsychiatric Symptoms in Alzheimer’s disease and dementia with lewy bodies. CNS Neurosci Ther. 2016;22(3):159–166.
   Google Scholar
• Zhang C, Zang Y, Song Q, et al. The efficacy of a “cocktail therapy” on Parkinson’s disease with dementia. Neuropsychiatr Dis Treat. 2019;15:1639–1647.
   Google Scholar
• Malegiannaki AC, Katsarou D, Liolios A, et al. Ageing and Down syndrome: neurocognitive characteristics and pharmacological treatment. Hell J Nucl Med. 2019;22:123–132.
   Google Scholar
• Khuanjing T, Palee S, Chattipakorn SC, et al. The effects of acetylcholinesterase inhibitors on the heart in acute myocardial infarction and heart failure: from cells to patient reports. Acta Physiol. 2020;228(2):e13396.
   Google Scholar
• Kawashiri T, Shimizu S, Shigematsu N, et al. Donepezil ameliorates oxaliplatin-induced peripheral neuropathy via a neuroprotective effect. J Pharmacol Sci. 2019;140(3):291–294.
   Google Scholar
• Wong JC, Thelin JT, Escayg A. Donepezil increases resistance to induced seizures in a mouse model of Dravet syndrome. Ann Clin Transl Neurol. 2019;6(8):1566–1571.
   Google Scholar
• Ferrier J, Bayet-Robert M, Dalmann R, et al. Cholinergic neurotransmission in the posterior insular cortex is altered in preclinical models of neuropathic pain: key role of muscarinic M2 receptors in donepezil-induced antinociception. J Neurosci. 2015;35(50):16418–16430.
   Google Scholar
• Piotrovsky V, Van Peer A, Van Osselaer N, et al. Galantamine population pharmacokinetics in patients with Alzheimer’s disease: modeling and simulations. J Clin Pharmacol. 2003;43(5):514–523.
   Google Scholar
• Huang F, Fu Y. A review of clinical pharmacokinetics and pharmacodynamics of galantamine, a reversible acetylcholinesterase inhibitor for the treatment of Alzheimer’s disease, in healthy subjects and patients. Curr Clin Pharmacol. 2010;5(2):115–124.
   Google Scholar
• Tayebati SK, Di Tullio MA, Amenta F. Effect of treatment with the cholinesterase inhibitor rivastigmine on vesicular acetylcholine transporter and choline acetyltransferase in rat brain. Clin Exp Hypertens. 2004;26(4):363–373.
   Google Scholar
• Jann MW, Shirley KL, Small GW. Clinical pharmacokinetics and pharmacodynamics of cholinesterase inhibitors. Clin Pharmacokinet. 2002;41(10):719–739.
   Google Scholar
• Lilienfeld S. Galantamine-a novel cholinergic drug with a unique dual mode of action for the treatment of patients with Alzheimer’s disease. CNS Drug Rev. 2002;8(2):159–176.
   Google Scholar
• Mannens GS, Snel CA, Hendrickx J, et al. The metabolism and excretion of galantamine in rats, dogs, and humans. Drug Metab Dispos. 2002;30(5):553–563.
   Google Scholar
• Noetzli M, Guidi M, Ebbing K, et al. Relationship of CYP2D6, CYP3A, POR, and ABCB1 genotypes with galantamine plasma concentrations. Ther Drug Monit. 2013;35(2):270–275.
   Google Scholar
• Bachus R, Bickel U, Thomsen T, et al. The O-demethylation of the antidementia drug galanthamine is catalysed by cytochrome P450 2D6. Pharmacogenetics. 1999;9(6):661–668.
   Google Scholar
• Bentué-Ferrer D, Tribut O, Polard E, et al. Clinically significant drug interactions with cholinesterase inhibitors: A guide for neurologists. CNS Drugs. 2003;17(13):947–963.
   Google Scholar
• Lin YT, Chou MC, Wu SJ, et al. Galantamine plasma concentration and cognitive response in Alzheimer’s disease. Peer J. 2019;7:e6887.
   Google Scholar
• Zhai XJ, Lu YN. Food-drug interactions: effect of capsaicin on the pharmacokinetics of galantamine in rats. Xenobiotica. 2012;42(11):1151–1155.
   Google Scholar
• Wallin AK, Wattmo C, Minthon L. Galantamine treatment in Alzheimer’s disease: response and long-term outcome in a routine clinical setting. Neuropsychiatr Dis Treat. 2011;7:565–576.
   Google Scholar
• Suh GH, Jung HY, Lee CU, et al. Effect of the apolipoprotein E epsilon4 allele on the efficacy and tolerability of galantamine in the treatment of Alzheimer’s disease. Dement Geriatr Cogn Disord. 2006;21(1):33–39.
   Google Scholar
• Babić T, Mahović Lakusić D, Sertić J, et al. ApoE genotyping and response to galanthamine in Alzheimer’s disease–a real life retrospective study. Coll Antropol. 2004;28(1):199–204.
   Google Scholar
• Prins ND, van der Flier WA, Knol DL, et al. The effect of galantamine on brain atrophy rate in subjects with mild cognitive impairment is modified by apolipoprotein E genotype: post-hoc analysis of data from a randomized controlled trial. Alzheimers Res Ther. 2014;6(4):47.
   Google Scholar
• Aerssens J, Raeymaekers P, Lilienfeld S, et al. APOE genotype: no influence on galantamine treatment efficacy nor on rate of decline in Alzheimer’s disease. Dement Geriatr Cogn Disord. 2001;12(2):69–77.
   Google Scholar
• Raskind MA, Peskind ER, Wessel T, et al. Galantamine in AD: A 6-month randomized, placebo-controlled trial with a 6-month extension. the galantamine USA-1 study group. Neurology. 2000;54(12):2261–2268.
   Google Scholar
• Weng PH, Chen JH, Chen TF, et al. CHRNA7 polymorphisms and response to cholinesterase inhibitors in Alzheimer’s disease. PLoS One. 2013;8(12):e84059.
   Google Scholar
• Carroll KM, DeVito EE, Yip SW, et al. Double-blind placebo-controlled trial of galantamine for methadone-maintained individuals with cocaine use disorder: secondary analysis of effects on illicit opioid use. Am J Addict. 2019;28(4):238–245.
   Google Scholar
• Sugarman DE, De Aquino JP, Poling J, et al. Feasibility and effects of galantamine on cognition in humans with cannabis use disorder. Pharmacol Biochem Behav. 2019;181:86–92.
   Google Scholar
• Njoku I, Radabaugh HL, Nicholas MA, et al. Chronic treatment with galantamine rescues reversal learning in an attentional set-shifting test after experimental brain trauma. Exp Neurol. 2019;315:32–41.
   Google Scholar
• Choueiry J, Blais CM, Shah D, et al. Combining CDP-choline and galantamine, an optimized α7 nicotinic strategy, to ameliorate sensory gating to speech stimuli in schizophrenia. Int J Psychophysiol. 2019;145:70–82.
   Google Scholar
• Koola MM. Potential role of Antipsychotic-Galantamine-Memantine combination in the treatment of positive, Cognitive, and Negative Symptoms of Schizophrenia. Mol. Neuropsychiatry.. 2018;4(3):134–148.
   Google Scholar
• Polinsky RJ. Clinical pharmacology of rivastigmine: a new-generation acetylcholinesterase inhibitor for the treatment of Alzheimer’s disease. Clin Ther. 1998;20(4):634–647.
   Google Scholar
• Tayebati SK, Di Tullio MA, Amenta F. Vesicular acetylcholine transporter (VAChT) in the brain of spontaneously hypertensive rats (SHR): effect of treatment with an acetylcholinesterase inhibitor. Clin Exp Hypertens. 2008;30(8):732–743.
   Google Scholar
• Birks JS, Grimley Evans J. Rivastigmine for Alzheimer’s disease. Cochrane Database Syst Rev. 2015;10:CD001191.
   Google Scholar
• Jia J, Ji Y, Feng T, et al. Sixteen-week interventional study to evaluate the clinical effects and safety of Rivastigmine Capsules in Chinese patients with Alzheimer’s disease. J Alzheimers Dis. 2019;72(4):1313–1322. JAD190791.
   Google Scholar
• Chen TH, Chou MC, Lai CL, et al. Factors affecting therapeutic response to Rivastigmine in Alzheimer’s disease patients in Taiwan. Kaohsiung J Med Sci. 2017;33(6):277–283.
   Google Scholar
• Zamani M, Mehri M, Kollaee A, et al. Pharmacogenetic study on the effect of Rivastigmine on PS2 and APOE genes in Iranian Alzheimer patients. Dement Geriatr Cogn Dis Extra. 2011;1(1):180–189.
   Google Scholar
• Sonali N, Tripathi M, Sagar R, et al. Clinical effectiveness of rivastigmine monotherapy and combination therapy in Alzheimer’s patients. CNS Neurosci Ther. 2013;19(2):91–97.
   Google Scholar
• Jasiecki J, Wasąg B. Butyrylcholinesterase protein ends in the pathogenesis of Alzheimer’s disease-could BCHE Genotyping be helpful in Alzheimer’s therapy? Biomolecules. 2019;9(10):E592.
   Google Scholar
• Ferris S, Nordberg A, Soininen H, et al. Progression from mild cognitive impairment to Alzheimer’s disease: effects of sex, butyrylcholinesterase genotype, and rivastigmine treatment. Pharmacogenet Genomics. 2009;19(8):635–646.
   Google Scholar
• Han HJ, Kwon JC, Kim JE, et al. Effect of rivastigmine or memantine add-on therapy is affected by butyrylcholinesterase genotype in patients with probable Alzheimer’s disease. Eur Neurol. 2015;73(1–2):23–28.
   Google Scholar
• Sobow T, Flirski M, Liberski P, et al. Plasma Abeta levels as predictors of response to rivastigmine treatment in Alzheimer’s disease. Acta Neurobiol Exp (Wars). 2007;67(2):131–139.
   Google Scholar
• Henderson EJ, Lord SR, Brodie MA, et al. Rivastigmine for gait stability in patients with Parkinson’s disease (ReSPonD): a randomised, double-blind, placebo-controlled, phase 2 trial. Lancet Neurol. 2016;15(3):249–258.
   Google Scholar
• Kandiah N, Pai M, Senanarong V, et al. Rivastigmine: the advantages of dual inhibition of acetylcholinesterase and butyrylcholinesterase and its role in subcortical vascular dementia and Parkinson’s disease dementia. Clin Interv Aging. 2017;12:697–707.
   Google Scholar
• Burgett RN, Farley TM, Beireis LA. Acute treatment of psychotic symptoms in a newly diagnosed Lewy body dementia patient with an accelerated titration schedule of rivastigmine and de-escalation of antipsychotics. BMJ Case Rep. 2019;12(9):e230193.
   Google Scholar
• Tsuno N, Mori T, Ishikawa I, et al. Efficacy of rivastigmine transdermal therapy on low food intake in patients with Alzheimer’s disease: the attitude towards food consumption in Alzheimer’s disease patients revive with Rivastigmine effects study. Geriatr Gerontol Int. 2019;19(7):571–576.
   Google Scholar
• Zhang HY. New insights into huperzine A for the treatment of Alzheimer’s disease. Acta Pharmacol Sin. 2012;33(9):1170–1175.
   Google Scholar
• Yang H, Du C, Li Q, et al. Discovery, molecular dynamic simulation and biological evaluation of structurally diverse cholinesterase inhibitors with new scaffold through shape-based pharmacophore virtual screening. Bioorg Chem. 2019;92:103294.
   Google Scholar
• Gul A, Bakht J, Mehmood F. Huperzine-A response to cognitive impairment and task switching deficits in patients with Alzheimer’s disease. J Chin Med Assoc. 2019;82(1):40–43.
   Google Scholar
• Rafii MS, Walsh S, Little JT, et al. A phase II trial of huperzine A in mild to moderate Alzheimer disease. Neurology. 2011;76(16):1389–1394.
   Google Scholar
• Gul A, Bakht J, Mehmood F. Huperzine-A response to cognitive impairment and task switching deficits in patients with Alzheimer’s disease. J Chin Med Assoc. 2018;S1726-4901(18):30226.
   Google Scholar
• Yang G, Wang Y, Tian J, et al. Huperzine A for Alzheimer’s disease: a systematic review and meta-analysis of randomized clinical trials. PLoS One. 2013;8(9):e74916.
   Google Scholar
• Sheng L, Qu Y, Yan J, et al. Population pharmacokinetic modeling and simulation of huperzine A in elderly Chinese subjects. Acta Pharmacol Sin. 2016;37(7):994–1001.
   Google Scholar
• Ma XC, Wang HX, Xin J, et al. Identification of cytochrome P450 1A2 as enzyme involved in the microsomal metabolism of Huperzine A. Eur J Pharmacol. 2003;461(2–3):89–92.
   Google Scholar
• Ma XC, Wang HX, Xin J, et al. Effects of huperzine A on liver cytochrome P-450 in rats. Acta Pharmacol Sin. 2003;24(8):831–835.
   Google Scholar
• Lin PP, Li XN, Yuan F, et al. Evaluation of the in vitro and in vivo metabolic pathway and cytochrome P450 inhibition/induction profile of Huperzine A. Biochem Biophys Res Commun. 2016;480(2):248–253.
   Google Scholar
• Sinz MW, Woolf TF. Characterization of the induction of rat microsomal cytochrome P450 by tacrine. Biochem Pharmacol. 1997;54(3):425–427.
   Google Scholar
• Gabriele M, Puccini P, Lucchi M, et al. Presence and inter-individual variability of carboxylesterases (CES1 and CES2) in human lung. Biochem Pharmacol. 2018;150:64–71.
   Google Scholar
• Li J, Yue M, Zhou D, et al. Abcb1a but not Abcg2 played a predominant role in limiting the brain distribution of Huperzine A in mice. Food Chem Toxicol. 2017;107(Pt A):68–73.
   Google Scholar
• Chen Y, Cheng G, Hu R, et al. A nasal temperature and pH dual-responsive in situ gel delivery system based on microemulsion of huperzine a: formulation, evaluation, and in vivo pharmacokinetic study. AAPS PharmSciTech. 2019;20(7):301.
   Google Scholar
• Mao XY, Zhou HH, Li X, et al. Huperzine a alleviates oxidative glutamate toxicity in Hippocampal HT22 cells via activating BDNF/TrkB-dependent PI3K/Akt/mTOR signaling pathway. Cell Mol Neurobiol. 2016;36(6):915–925.
   Google Scholar
• Shih CC, Chen PY, Chen MF, et al. Differential blockade by huperzine A and donepezil of sympathetic nicotinic acetylcholine receptor-mediated nitrergic neurogenic dilations in porcine basilar arteries. Eur J Pharmacol. 2020;868:172851.
   Google Scholar
• Kang X, Liu C, Shen P, et al. Genomic characterization provides new insights into the biosynthesis of the secondary metabolite huperzine a in the endophyte colletotrichum gloeosporioides Cg01. Front Microbiol. 2019;9:3237.
   Google Scholar
• Xu M, Heidmarsson S, Thorsteinsdottir M, et al. Infraspecific variation of huperzine A and B in Icelandic Huperzia selago complex. Planta Med. 2019;85(2):160–168.
   Google Scholar
• Zaki AG, El-Shatoury EH, Ahmed AS, et al. Production and enhancement of the acetylcholinesterase inhibitor, huperzine A, from an endophytic Alternaria brassicae AGF041. Appl Microbiol Biotechnol. 2019;103(14):5867–5878.
   Google Scholar
• MacGowan SH, Wilcock GK, Scott M. Effect of gender and apolipoprotein E genotype on response to anticholinesterase therapy in Alzheimer’s disease. Int J Geriatr Psychiatry. 1998;13(9):625–630.
   Google Scholar
• Farlow MR, Lahiri DK, Poirier J, et al. Treatment outcome of tacrine therapy depends on apolipoprotein genotype and gender of the subjects with Alzheimer’s disease. Neurology. 1998;50(3):669–677.
   Google Scholar
• Fontana RJ, Turgeon DK, Woolf TF, et al. The caffeine breath test does not identify patients susceptible to tacrine hepatotoxicity. Hepatology. 1996;23(6):1429–1435.
   Google Scholar
• Schneider LS, Farlow M. Combined tacrine and estrogen replacement therapy in -patients with Alzheimer’s Disease b. Ann N Y Acad Sci. 1997;826(1):317–322.
   Google Scholar
• Sjögren M, Hesse C, Basun H, et al. Tacrine and rate of progression in Alzheimer’s disease–relation to ApoE allele genotype. J Neural Transm (Vienna). 2001;108(4):451–458.
   Google Scholar
• Yoon BK, Kim DK, Kang Y, et al. Hormone replacement therapy in postmenopausal women with Alzheimer’s disease: a randomized, prospective study. Fertil Steril. 2003;79(2):274–280.
   Google Scholar
• Rigaud AS, Traykov L, Caputo L, et al. The apolipoprotein E epsilon4 allele and the response to tacrine therapy in Alzheimer’s disease. Eur J Neurol. 2000;7(3):255–258.
   Google Scholar
• Becquemont L, Le Bot MA, Riche C, et al. Use of heterologously expressed human cytochrome P450 1A2 to predict tacrine-fluvoxamine drug interaction in man. Pharmacogenetics. 1998;8(2):101–108.
   Google Scholar
• Alfirevic A, Mills T, Carr D, et al. Tacrine-induced liver damage: an analysis of 19 candidate genes. Pharmacogenet Genomics. 2007;17(12):1091–1100.
   Google Scholar
• Simon T, Becquemont L, Mary-Krause M, et al. Combined glutathione-S-transferase M1 and T1 genetic polymorphism and tacrine hepatotoxicity. Clin Pharmacol Ther. 2000;67(4):432–437.
   Google Scholar
• Becquemont L, Lecoeur S, Simon T, et al. Glutathione S-transferase theta genetic polymorphism might influence tacrine hepatotoxicity in Alzheimer’s patients. Pharmacogenetics. 1997;7(3):251–253.
   Google Scholar
• De Sousa M, Pirmohamed M, Kitteringham NR, et al. No association between tacrine transaminitis and the glutathione transferase theta genotype in patients with Alzheimer’s disease. Pharmacogenetics. 1998;8(4):353–355.
   Google Scholar
• Benfante R, Di Lascio S, Cardani S, et al. Acetylcholinesterase inhibitors targeting the cholinergic anti-inflammatory pathway: a new therapeutic perspective in aging-related disorders. Aging Clin Exp Res. 2019. DOI:10.1007/s40520-019-01359-4.
   Google Scholar
• Hayashi Y, Lin HT, Lee CC, et al. Effects of neural stem cell transplantation in Alzheimer’s disease models. J Biomed Sci. 2020;27(1):29.
   Google Scholar
• Cacabelos R. How plausible is an Alzheimer’s disease vaccine? Expert Opin Drug Discov. 2020;151:1–6. Epub 2019 Sep 17.
   Google Scholar
• Cacabelos R. Pathoepigenetics: the role of epigenetic biomarkers in disease pathogenesis. In: Cacabelos R, editor. Pharmacoepigenetics. Oxford: Academic Press/ Elsevier; 2019. p. 139–189.
   Google Scholar
• Fink HA, Jutkowitz E, McCarten JR, et al. Pharmacologic interventions to prevent cognitive decline, mild cognitive impairment, and Clinical Alzheimer-type dementia: a systematic review. Ann Intern Med. 2018;168(1):39–51.
   Google Scholar
• Folch J, Busquets O 3, Ettcheto M 3, et al. Memantine for the treatment of dementia: a review on its current and future applications. J Alzheimers Dis. 2018;62(3):1223–1240.
   Google Scholar
• McShane R, Westby MJ, Roberts E, et al. Memantine for dementia. Cochrane Database Syst Rev. 2019;3:CD003154.
   Google Scholar
• Blanco-Silvente L, Castells X, Garre-Olmo J, et al. Study of the strength of the evidence and the redundancy of the research on pharmacological treatment for Alzheimer’s disease: a cumulative meta-analysis and trial sequential analysis. Eur J Clin Pharmacol. 2019;75(12):1659–1667.
   Google Scholar
• Cui CC, Sun Y, Wang XY, et al. The effect of anti-dementia drugs on Alzheimer disease-induced cognitive impairment: A network meta-analysis. Medicine (Baltimore). 2019;98(27):e16091.
   Google Scholar
• Thancharoen O, Limwattananon C, Waleekhachonloet O, et al. Ginkgo biloba Extract (EGb761), Cholinesterase inhibitors, and memantine for the treatment of mild-to-moderate Alzheimer’s disease: a network meta-analysis. Drugs Aging. 2019;36(5):435–452.
   Google Scholar
• Knight R, Khondoker M, Magill N, et al. A systematic review and meta-analysis of the effectiveness of acetylcholinesterase inhibitors and memantine in treating the cognitive symptoms of dementia. Dement Geriatr Cogn Disord. 2018;45(3–4):131–151.
   Google Scholar
• Arai H, Hashimoto N, Sumitomo K, et al. Disease state changes and safety of long-term donepezil hydrochloride administration in patients with Alzheimer’s disease: japan-great outcome of long-term trial with Donepezil (J-GOLD). Psychogeriatrics. 2018;18(5):402–411.
   Google Scholar
• Kennedy RE, Cutter GR, Fowler ME, et al. Association of concomitant use of cholinesterase inhibitors or memantine with cognitive decline in Alzheimer clinical trials: a meta-analysis. JAMA Network Open. 2018;1(7):e184080.
   Google Scholar
• Glinz D, Gloy VL, Monsch AU, et al. Acetylcholinesterase inhibitors combined with memantine for moderate to severe Alzheimer’s disease: a meta-analysis. Swiss Med Wkly. 2019;149:w20093.
   Google Scholar
• Tsoi KK, Chan JY, Chan FC, et al. Monotherapy is good enough for patients with mild-to-moderate Alzheimer’s disease: a network meta-analysis of 76 randomized controlled trials. Clin Pharmacol Ther. 2019;105(1):121–130.
   Google Scholar
• Dou KX, Tan MS, Tan CC, et al. Comparative safety and effectiveness of cholinesterase inhibitors and memantine for Alzheimer’s disease: a network meta-analysis of 41 randomized controlled trials. Alzheimers Res Ther. 2018;10(1):126.
   Google Scholar
• Huisa BN, Thomas RG, Jin S, et al. Memantine and acetylcholinesterase inhibitor use in Alzheimer’s disease clinical trials: potential for confounding by indication. J Alzheimers Dis. 2019;67(2):707–713.
   Google Scholar
• Han JY, Besser LM, Xiong C, et al. Cholinesterase inhibitors may not benefit mild cognitive impairment and mild Alzheimer disease dementia. Alzheimer Dis Assoc Disord. 2019;33(2):87–94.
   Google Scholar
• Secnik J, Schwertner E, Alvarsson M, et al. Cholinesterase inhibitors in patients with diabetes mellitus and dementia: an open-cohort study of ~23 000 patients from the Swedish Dementia Registry. BMJ Open Diabetes Res Care. 2020;8(1):e000833.
   Google Scholar
• Ku LE, Li CY, Sun Y. Can persistence with cholinesterase inhibitor treatment lower mortality and health-care costs among patients with Alzheimer’s disease? A population-based study in Taiwan. Am J Alzheimers Dis Other Demen. 2018;33(2):86–92.
   Google Scholar
• Linna M, Vuoti S, Silander K, et al. Impact of Anti-Dementia medication on the risk of death and causes of death in Alzheimer’s disease. J Alzheimers Dis. 2019;71(4):1297–1308.
   Google Scholar
• Noufi P, Khoury R, Jeyakumar S, et al. Use of Cholinesterase inhibitors in non-Alzheimer’s dementias. Drugs Aging. 2019;36(8):719–731.
   Google Scholar
• Jin BR, Liu HY. Comparative efficacy and safety of cognitive enhancers for treating vascular cognitive impairment: systematic review and Bayesian network meta-analysis. Neural Regen Res. 2019;14(5):805–816.
   Google Scholar
• Eldufani J, Blaise G. The role of acetylcholinesterase inhibitors such as neostigmine and rivastigmine on chronic pain and cognitive function in aging: A review of recent clinical applications. Alzheimers Dement. 2019;5:175–183.
   Google Scholar
• Kim JO, Lee SJ, Pyo JS. Effect of acetylcholinesterase inhibitors on post-stroke cognitive impairment and vascular dementia: a meta-analysis. PLoS One. 2020;15(2):e0227820.
   Google Scholar
• Tan ECK, Johnell K, Garcia-Ptacek S, et al. Acetylcholinesterase inhibitors and risk of stroke and death in people with dementia. Alzheimers Dement. 2018 Jul;14(7):944–951.
   Google Scholar
• Haywood WM, Mukaetova-Ladinska EB. Sex influences on cholinesterase inhibitor treatment in elderly individuals with Alzheimer’s disease. Am J Geriatr Pharmacother. 2006;4(3):273–286.
   Google Scholar
• Giacobini E, Pepeu G. Sex and gender differences in the brain cholinergic system and in the response to therapy of Alzheimer disease with cholinesterase inhibitors. Curr Alzheimer Res. 2018;15(11):1077–1084.
   Google Scholar
• Wallin AK, Blennow K, Andreasen N, et al. CSF biomarkers for Alzheimer’s disease: levels of beta-amyloid, tau, phosphorylated tau related to clinical symptoms and survival. Dement Geriatr Cogn Disord. 2006;21(3):131–138.
   Google Scholar
• Stefanova E, Blennow K, Almkvist O, et al. Cerebral glucose metabolism, cerebrospinal fluid-beta-amyloid1-42 (CSF-Abeta42), tau and apolipoprotein E genotype in long-term rivastigmine and tacrine treated Alzheimer disease (AD) patients. Neurosci Lett. 2003;338(2):159–163.
   Google Scholar
• Haake A, Nguyen K, Friedman L, et al. An update on the utility and safety of cholinesterase inhibitors for the treatment of Alzheimer’s disease. Expert Opin Drug Saf. 2020;1–11. DOI:10.1080/14740338.2020.1721456.
   Google Scholar
• Eshetie TC, Nguyen TA, Gillam MH, et al. Medication Use for Comorbidities in People with Alzheimer’s Disease: an Australian Population-Based Study. Pharmacotherapy. 2019;39(12):1146–1156.
   Google Scholar
• Tan ECK, Johnell K, Bell JS, et al. Do acetylcholinesterase inhibitors prevent or delay psychotropic prescribing in people with dementia? Analyses of the swedish dementia registry. Am J Geriatr Psychiatry. 2020;28(1):108–117.
   Google Scholar
• Ballard C, Creese B, Corbett A, et al. Atypical antipsychotics for the treatment of behavioral and psychological symptoms in dementia, with a particular focus on longer term outcomes and mortality. Expert Opin Drug Saf. 2011;10(1):35–43.
   Google Scholar
• Torrellas C, Carril JC, Cacabelos R. Optimization of antidepressant use with pharmacogenetic strategies. Cur Genomics. 2017;18:442–449.
   Google Scholar
• Orsel K, Taipale H, Tolppanen AM, et al. Psychotropic drugs use and psychotropic polypharmacy among persons with Alzheimer’s disease. Eur Neuropsychopharmacol. 2018;28(11):1260–1269.
   Google Scholar
• Dalmizrak O, Teralı K, Yetkin O, et al. Computational and experimental studies on the interaction between butyrylcholinesterase and fluoxetine: implications in health and disease. Xenobiotica. 2019;49(7):803–810.
   Google Scholar
• Zhang Y, Li S, Wang Y, et al. Potential pharmacokinetic drug⁻drug interaction between harmine, a cholinesterase inhibitor, and memantine, a non-competitive n-methyl-d-aspartate receptor antagonist. Molecules. 2019;24(7):E1430.
   Google Scholar
• Winblad B 1, Engedal K, Soininen H, et al. Donepezil nordic study group. A 1-year, randomized, placebo-controlled study of donepezil in patients with mild to moderate AD. Neurology. 2001 Aug 14;57(3):489–495.
   Google Scholar
• Lum ZK, Suministrado MSP, Venketasubramanian N, et al. Medication compliance in Singaporean patients with Alzheimer’s disease. Singapore Med J. 2019;60(3):154–160. #.
   Google Scholar
• Carney G, Bassett K, Wright JM, et al. Comparison of cholinesterase inhibitor safety in real-world practice. Alzheimers Dement. 2019;5:732–739.
   Google Scholar
• Kazmierski J, Messini-Zachou C, Gkioka M, et al. The impact of a long-term rivastigmine and donepezil treatment on all-cause mortality in patients with Alzheimer’s disease. Am J Alzheimers Dis Other Demen. 2018;33(6):385–393.
   Google Scholar
• Fleet JL, McArthur E, Patel A, et al. Risk of rhabdomyolysis with donepezil compared with rivastigmine or galantamine: a population-based cohort study. CMAJ. 2019;191(37):E1018–E1024.
   Google Scholar
• Lampela P, Tolppanen AM, Koponen M, et al. Asthma and chronic obstructive pulmonary disease as a comorbidity and association with the choice of antidementia medication among persons with Alzheimer’s disease. J Alzheimers Dis. 2020;73(3):1243–1251.
   Google Scholar
• Pu Z, Xu W, Lin Y, et al. Donepezil decreases heart rate in elderly patients with Alzheimer’s disease. Int J Clin Pharmacol Ther. 2019;57(2):94–100.
   Google Scholar
• Won DY, Byun SJ, Jeong JS, et al. Association between acetylcholinesterase inhibitors and osteoporotic fractures in older persons with Alzheimer’s disease. J Am Med Dir Assoc. 2020;S1525-8610(19):30841–30842.
   Google Scholar
• Tamimi I, Nicolau B, Eimar H, et al. Acetylcholinesterase inhibitors and the risk of osteoporotic fractures: nested case-control study. Osteoporos Int. 2018;29(4):849–857.
   Google Scholar
• Yiannopoulou KG, Anastasiou AI, Kyrozis A, et al. Donepezil treatment for Alzheimer’s disease in chronic dialysis patients. Case Rep Nephrol Dial. 2019;9(3):126–136.
   Google Scholar
• Renn BN, Asghar-Ali AA, Thielke S, et al. A systematic review of practice guidelines and recommendations for discontinuation of cholinesterase inhibitors in dementia. Am J Geriatr Psychiatry. 2018;26(2):134–147.
   Google Scholar
• Ueda K, Katayama S, Arai T, et al. Efficacy, safety, and tolerability of switching from oral cholinesterase inhibitors to rivastigmine transdermal patch with 1-step titration in patients with mild to moderate Alzheimer’s disease: a 24-week, open-label, multicenter study in Japan. Dement Geriatr Cogn Dis Extra. 2019;9(2):302–318.
   Google Scholar
• Blesa R, Toriyama K, Ueda K, et al. Strategies for continued successful treatment in patients with alzheimer’s disease: an overview of switching between pharmacological agents. Curr Alzheimer Res. 2018;15(10):964–974.
   Google Scholar
• Moss DE. Is Combining an anticholinergic with a cholinesterase inhibitor a good strategy for high-level CNS cholinesterase inhibition? J Alzheimers Dis. 2019;71(4):1099–1103.
   Google Scholar
• Işık M. The binding mechanisms and inhibitory effect of intravenous anesthetics on AChE in vitro and in vivo: kinetic analysis and molecular docking. Neurochem Res. 2019;44(9):2147–2155.
   Google Scholar
• MacKenzie M, Hall R. Pharmacogenomics and pharmacogenetics for the intensive care unit: a narrative review. Can J Anaesth. 2017;64(1):45–64.
   Google Scholar
• Zhang X, Jiang X, Huang L, et al. Central cholinergic system mediates working memory deficit induced by anesthesia/surgery in adult mice. Brain Behav. 2018;8(5):e00957.
   Google Scholar
• Philpot RM, Ficken M, Johns BE, et al. Spatial memory deficits in mice induced by chemotherapeutic agents are prevented by acetylcholinesterase inhibitors. Cancer Chemother Pharmacol. 2019;84(3):579–589.
   Google Scholar
• Giacconi R, Giuli C, Casoli T, et al. Acetylcholinesterase inhibitors in Alzheimer’s disease influence Zinc and Copper homeostasis. J Trace Elem Med Biol. 2019;55:58–63.
   Google Scholar
• Stojiljković MP, Škrbić R, Jokanović M, et al. Efficacy of antidotes and their combinations in the treatment of acute carbamate poisoning in rats. Toxicology. 2018;408:113–124.
   Google Scholar
• May BH, Feng M, Hyde AJ, et al. Comparisons between traditional medicines and pharmacotherapies for Alzheimer disease: A systematic review and meta-analysis of cognitive outcomes. Int J Geriatr Psychiatry. 2018;33(3):449–458.
   Google Scholar
• McEneny-King A, Osman W, Edginton AN, et al. Cytochrome P450 binding studies of novel tacrine derivatives: predicting the risk of hepatotoxicity. Bioorg Med Chem Lett. 2017;27(11):2443–2449.
   Google Scholar
• Djalalov S, Yong J, Beca J, et al. Genetic testing in combination with preventive donepezil treatment for patients with amnestic mild cognitive impairment: an exploratory economic evaluation of personalized medicine. Mol Diagn Ther. 2012;16(6):389–399.
   Google Scholar
• Whitehair DC, Sherzai A, Emond J, et al. Alzheimer’s Disease Cooperative Study. Influence of apolipoprotein E varepsilon4 on rates of cognitive and functional decline in mild cognitive impairment. Alzheimers Dement. 2010;6(5):412–419.
   Google Scholar
• Kanaya K, Abe S, Sakai M, et al. Changes in cognitive functions of patients with dementia of the Alzheimer type following long-term administration of donepezil hydrochloride: relating to changes attributable to differences in apolipoprotein E phenotype. Geriatr Gerontol Int. 2010;10(1):25–31.
   Google Scholar
• Jack CR, Petersen RC, Grundman M, et al. Members of the Alzheimer’s disease cooperative study (ADCS). longitudinal MRI findings from the vitamin E and donepezil treatment study for MCI. Neurobiol Aging. 2008;29(9):1285–1295.
   Google Scholar
• Tricco AC, Ashoor HM, Soobiah C, et al. Comparative effectiveness and safety of cognitive enhancers for treating alzheimer’s disease: systematic review and network metaanalysis. J Am Geriatr Soc. 2018;66(1):170–178.
   Google Scholar